T2 BIOSYSTEMS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.84 USD | +3.65% |
|
-4.05% | -54.74% |
| Apr. 23 | Top Premarket Decliners | MT |
| Apr. 01 | T2 Biosystems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 132.5 | 54.61 | 183.5 | 85.67 | 10.39 | 25.42 |
| Enterprise Value (EV) 1 | 126.3 | 92.76 | 189.2 | 111.8 | 59.28 | 59.22 |
| P/E ratio | - | - | -3.21 x | -1.67 x | -0.12 x | -0.33 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 12.6 x | 6.55 x | 10.1 x | 3.05 x | 0.47 x | 3.53 x |
| EV / Revenue | 12 x | 11.1 x | 10.4 x | 3.98 x | 2.66 x | 8.23 x |
| EV / EBITDA | -3.01 x | -1.86 x | -4.92 x | -2.68 x | -1.1 x | -1.28 x |
| EV / FCF | -5.12 x | -3.65 x | -6.21 x | -5.4 x | -2.09 x | -2.57 x |
| FCF Yield | -19.5% | -27.4% | -16.1% | -18.5% | -47.9% | -38.9% |
| Price to Book | - | -1.74 x | 21 x | -6.66 x | -0.28 x | -0.91 x |
| Nbr of stocks (in thousands) | 8.81 | 9.34 | 29.6 | 33.2 | 73.2 | 4,050 |
| Reference price 2 | 15,050 | 5,850 | 6,200 | 2,581 | 142.0 | 6.275 |
| Announcement Date | 3/14/19 | 3/16/20 | 3/31/21 | 3/23/22 | 3/31/23 | 4/1/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 10.5 | 8.335 | 18.13 | 28.06 | 22.3 | 7.193 |
| EBITDA 1 | -41.96 | -49.86 | -38.49 | -41.7 | -54 | -46.29 |
| EBIT 1 | -44.41 | -52.06 | -40.2 | -42.97 | -55.04 | -47.15 |
| Operating Margin | -422.92% | -624.57% | -221.72% | -153.16% | -246.78% | -655.54% |
| Earnings before Tax (EBT) 1 | -51.15 | -59.01 | -46.8 | -49.24 | -62 | -50.08 |
| Net income 1 | -51.15 | -59.01 | -46.8 | -49.24 | -62 | -50.08 |
| Net margin | -487.17% | -707.93% | -258.12% | -175.5% | -277.98% | -696.19% |
| EPS | - | - | -1,929 | -1,550 | -1,222 | -19.19 |
| Free Cash Flow 1 | -24.66 | -25.39 | -30.45 | -20.7 | -28.4 | -23.07 |
| FCF margin | -234.82% | -304.62% | -167.97% | -73.77% | -127.31% | -320.67% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/14/19 | 3/16/20 | 3/31/21 | 3/23/22 | 3/31/23 | 4/1/24 |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.428 | 6.98 | 7.234 | 5.911 | 3.677 | 5.483 | 2.078 | 1.964 | 1.472 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -12.21 | -10.28 | -14.86 | -15.02 | -15.8 | -9.834 | -13.69 | -13.05 | -11.1 |
| Operating Margin | -164.4% | -147.26% | -205.38% | -254.09% | -429.7% | -179.35% | -658.66% | -664.51% | -753.8% |
| Earnings before Tax (EBT) 1 | -13.96 | -12.14 | -16.5 | -18.03 | -17.38 | -10.41 | -17.96 | -6.347 | -15.42 |
| Net income 1 | -13.96 | -12.14 | -16.5 | -18.03 | -17.7 | -10.41 | -17.96 | -6.347 | -15.42 |
| Net margin | -187.96% | -173.98% | -228.02% | -305.09% | -481.51% | -189.91% | -864.53% | -323.17% | -1,047.89% |
| EPS 2 | -400.0 | -350.0 | -500.0 | -500.0 | -295.0 | -141.0 | -132.0 | -8.000 | -3.450 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 2/17/22 | 5/5/22 | 8/15/22 | 11/10/22 | 3/13/23 | 5/22/23 | 8/7/23 | 11/15/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 38.2 | 5.74 | 26.1 | 48.9 | 33.8 |
| Net Cash position 1 | 6.29 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -0.7651 x | -0.1491 x | -0.6254 x | -0.9054 x | -0.7303 x |
| Free Cash Flow 1 | -24.7 | -25.4 | -30.5 | -20.7 | -28.4 | -23.1 |
| ROE (net income / shareholders' equity) | -804% | 522% | 370% | 2,358% | 236% | 148% |
| ROA (Net income/ Total Assets) | -46.6% | -70.1% | -46.7% | -38.5% | -72.5% | -85.3% |
| Assets 1 | 109.8 | 84.14 | 100.2 | 128 | 85.49 | 58.73 |
| Book Value Per Share | - | -3,357 | 295.0 | -388.0 | -514.0 | -6.910 |
| Cash Flow per Share | - | 1,089 | 567.0 | 668.0 | 134.0 | 3.870 |
| Capex 1 | 0.59 | 0.76 | 0.8 | 0.46 | 0.34 | 0.19 |
| Capex / Sales | 5.65% | 9.13% | 4.43% | 1.64% | 1.52% | 2.67% |
| Announcement Date | 3/14/19 | 3/16/20 | 3/31/21 | 3/23/22 | 3/31/23 | 4/1/24 |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -54.74% | 24.97M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B | |
| +26.76% | 32.03B |
- Stock Market
- Equities
- TTOO Stock
- Financials T2 Biosystems, Inc.
